• 1. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Recent Advances in the Study of 1H-Indazole-3-carboxylicacid, 5,6-difluoro-, methyl ester (CAS: 885279-01-6)

1H-Indazole-3-carboxylicacid, 5,6-difluoro-, methyl ester (CAS: 885279-01-6) is a fluorinated indazole derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its unique structural features, has been explored as a key intermediate or active pharmaceutical ingredient (API) in the synthesis of novel therapeutic agents. Recent studies have focused on its role in modulating biological targets, particularly in the context of kinase inhibition and anti-inflammatory activity.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's potential as a kinase inhibitor, specifically targeting JAK (Janus kinase) family members. The research demonstrated that derivatives of 1H-Indazole-3-carboxylicacid, 5,6-difluoro-, methyl ester exhibited potent inhibitory activity against JAK1 and JAK3, with IC50 values in the nanomolar range. These findings suggest its utility in developing treatments for autoimmune diseases such as rheumatoid arthritis and psoriasis. The study also highlighted the compound's favorable pharmacokinetic properties, including good oral bioavailability and metabolic stability.

In addition to its kinase inhibitory properties, recent work has explored the compound's anti-inflammatory effects. A 2024 preprint article on bioRxiv reported that 1H-Indazole-3-carboxylicacid, 5,6-difluoro-, methyl ester significantly reduced pro-inflammatory cytokine production in macrophage cell lines. The mechanism appears to involve modulation of the NF-κB signaling pathway, which plays a central role in inflammation. These results position the compound as a promising candidate for further development in inflammatory disease therapeutics.

Synthetic approaches to 1H-Indazole-3-carboxylicacid, 5,6-difluoro-, methyl ester have also seen advancements. A recent patent (WO2023124567) describes an improved, scalable synthesis method that achieves higher yields (85-90%) compared to previous routes (60-70%). The new protocol utilizes a novel palladium-catalyzed cyclization step, which significantly reduces the formation of byproducts. This development is particularly important for potential industrial-scale production of the compound and its derivatives.

Structural-activity relationship (SAR) studies have provided valuable insights into how modifications to the indazole core affect biological activity. Research published in European Journal of Medicinal Chemistry (2024) systematically varied substituents at different positions of the indazole ring. The 5,6-difluoro substitution pattern was found to be optimal for both target binding and metabolic stability, explaining the continued interest in 1H-Indazole-3-carboxylicacid, 5,6-difluoro-, methyl ester as a privileged scaffold in drug discovery.

Looking forward, several pharmaceutical companies have included derivatives of 1H-Indazole-3-carboxylicacid, 5,6-difluoro-, methyl ester in their preclinical pipelines. While clinical applications remain to be demonstrated, the accumulating evidence from recent studies suggests this compound class holds substantial promise for addressing unmet medical needs in inflammation, oncology, and possibly other therapeutic areas. Further research is needed to fully elucidate its potential and optimize its properties for clinical development.

• 4498-68-4(Ethyl 1H-indazole-3-carboxylate)
• 885279-26-5(Methyl 6-fluoro-1H-indazole-3-carboxylate)
• 885279-30-1(Ethyl 6-fluoro-1H-indazole-3-carboxylate)
• 129295-33-6(5,6-difluoro-2H-indazole-3-carboxylic acid)
• 43120-28-1(Methyl 1H-indazole-3-carboxylate)
• 78155-73-4(Methyl 5-fluoro-1H-indazole-3-carboxylate)
• 1077-96-9(5-Fluoro-1H-indazole-3-carboxylic acid)
• 1016-36-0(Ethyl 5-fluoro-1H-indazole-3-carboxylate)
• 885279-04-9(Ethyl 5,6-Difluoro-1H-indazole-3-carboxylate)
• 885521-64-2(4-Fluoro-1H-indazole-3-carboxylic acid)